Biotech Business - June 15, 2022
TILT Biotherapeutics receives over 10 million USD in financing
TILT Biotherapeutics has completed the first close of its financing round raising 10.7 million USD. The round was led by Lifeline Ventures and was joined by Tesi (Finnish Industry Investment Ltd). “We support resilient founders. We saw early on the enormous potential in TILT’s innovative approach to boost the patient’s T cell immune response to […]
Biotech Business - June 8, 2022
Elicera Therapeutics receives 2.5 million EUR in EU funding
Elicera Therapeutics has been awarded funding from the European Innovation Council (EIC) Accelerator Programme. The grant is sufficient to fully fund Elicera’s planned clinical phase I/II-study evaluating its CAR T-cell therapy ELC-301 in the treatment of B-cell lymphoma, the company states. “This grant has major positive implications for the development of our CAR T-cell therapy, […]
Biotech Business - June 1, 2022
Spago Nanomedical carries out a rights issue of up to 61.8 million SEK
The Board of Directors of Spago Nanomedical has resolved to carry out a rights issue with preferential rights for existing shareholders of up to 61.8 MSEK before issue costs. Four (4) shares in Spago Nanomedical entitle for subscription of five (5) new shares in the Rights Issue at a subscription price of SEK 1.20 per […]
Financing - May 31, 2022
Capitainer raises 34 million SEK
Capitainer has closed a share issue to capitalize on growing interest in home-sampling with its new qDBS dried blood spot testing system. The investment round, led by Sciety, brought in both existing and new industry specialist investors and several board members and the CEO. “Once again we are delighted to have secured such strong support […]
Financing - May 7, 2022
Sidekick Health raises 55 million USD
Sidekick Health has raised 55 million USD in Series B funding. The round was led by London-based venture capital firm Novator Ventures, with additional participation from Wellington Partners, Asabys Partners, and Frumtak Ventures, as well as a US-based strategic investor that will be revealed at a later stage. Read more: Filling a void in chronic […]
Biotech Business - May 5, 2022
BioInvent receives milestone payment
BioInvent International receives a milestone payment from Bayer/Hope Medicine following clinical progression of an out-licensed antibody. BioInvent receives EUR 500,000 following the enrollment of the first patient in a Phase 2 trial of HMI-115 for the treatment of endometriosis in pre-menopausal women. HMI-115 is an anti-prolactin receptor antibody discovered using BioInvent’s n-CoDeR phage display antibody […]
